India drug giant Sun Pharmaceuticals has received approval from the U.S. FDA for anti-inflammatory eye drug, BromSite, helping the drugmaker increase its specialty branded drugs presence in the U.S. pharmaceuticals market.
Sun is looking for a substantial share in the growing NSAID market in the U.S. BromSite will be commercialized through New Jersey-based Sun Ophthalmics, the newly formed U.S. division of the company, and will target both eye care practitioners as well as patients.
The newly approved drug is used for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. According to Sun, it is first NSAID approved for such conditions. The drug is slated to enter the U.S. markets in the second half of 2016.